United Kingdom

Pain

We offer a comprehensive range of pain management solutions that enable you to respond effectively to the individual requirements of each patient.


Around 28 million adults in the UK are affected by persistent/chronic pain,1 resulting in a major impact on their quality of life and inability to maintain regular work.

Most patients with chronic pain can be well managed in the community or local hospitals by appropriately trained members of interdisciplinary Pain Management Services; however, some patients with more complex chronic pain problems require management in highly specialised Pain Management centres.

Breakthrough pain is common in cancer patients

Breakthrough cancer pain affects cancer patients who already experience controlled every day pain. It comes on suddenly and quickly, often without warning, it is usually short-lived – typically lasting about 30-60 minutes, although the episodes can vary. 

Oncology nurses have an important role in identifying and managing breakthrough cancer pain and in referring difficult cases to Pain Specialists. 

Effentora® (fentanyl buccal tablet)

Effentora® is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain. BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. 

Patients receiving maintenance opioid therapy are those who are taking at least 60mg of oral morphine daily, at least 25mcg of transdermal fentanyl per hour, at least 30mg of oxycodone daily, at least 8mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.2

Actiq® (oral transmucosal fentanyl citrate)

Actiq® is indicated for the management of breakthrough pain in cancer patients 16 years of age and older who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.3 It is a compressed lozenge with integral oromucosal applicator.

Patients receiving maintenance opioid therapy are those who are taking at least 60mg of oral morphine daily, at least 25mcg of transdermal fentanyl per hour, at least 30mg of oxycodone daily, at least 8mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer.3

Axsain® (capsaicin cream 0.075%)

Axsain® cream contains 0.075% capsaicin and is indicated for the treatment of painful peripheral diabetic neuropathy (PDN), and post-herpetic neuralgia (PHN) after open skin lesions have healed. 

Capsaicin binds to skin-based nociceptors, initially causing localised neurogenic inflammation then cumulatively depleting inflammatory agents including Substance P.4

Zacin® (capsaicin cream 0.025%)

Zacin® cream contains 0.025% capsaicin, and is indicated for the symptomatic relief of pain associated with osteoarthritis.

Capsaicin binds to skin-based nociceptors, initially causing localised neurogenic inflammation then cumulatively depleting inflammatory agents including Substance P.5

 

  • For factual, scientific-based information about Effentora®, Actiq®, Axsain® and Zacin®, contact Teva’s Medical Information Service via e-mail medinfo@tevauk.com or call 0207 540 7117
  • Further information, including Prescribing Information for Effentora®, Actiq®, Axsain® and Zacin® is available from the product catalogue


__________________________________________________________________________________________

References:

[1] Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies. BMJ Open. Last accessed: May 2019

[2] Effentora® (fentanyl buccal tablet) Summary of Product Characteristics.

[3] Actiq® (oral transmucosal fentanyl citrate) Summary of Product Characteristics.

[4] Axsain® (capsaicin cream 0.075%) Summary of Product Characteristics.

[5] Zacin® (capsaicin cream 0.025%) Summary of Product Characteristics. 

Teva Ref: HC615